CS 3030

Drug Profile

CS 3030

Alternative Names: CS-3030

Latest Information Update: 24 Jan 2008

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thromboembolism

Most Recent Events

  • 24 Nov 2007 Discontinued - Phase-I for Thromboembolism in USA (PO)
  • 06 Apr 2006 Phase-I clinical trials in Thromboembolism in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top